Lentivirus Research - New imminent?5 Aug 2023 21:00
I would love to get a view from some of the well researched people on here and other science orientated people but With the lack of an update since June 2nd when FDA informed Vlad, I have done some research on the lentivirus so see whether we are in the news zone. It does look like we are. Considering vlad had an idea of what the issue was whilst the FDA was reviewing the IND during the statuatory 30 days, it would suggest the new lentivirus was already out on order. As well as this, the CH letter RNS confirms that the lentivirus was still being re-manufactured. Therefore providing there has been no logistical issue with the only 1 issue FDA found, I suspect we may see news anyway NOW. We definately in the buy zone and as confirmed by Zak mir who stated 2.4p is expected in August.
"Creating a lentiviral vector for CAR-T cell therapy is a complex process that involves several steps and can take a varying amount of time based on the specifics involved. Broadly, the process includes designing the viral vector, cloning the CAR gene into the vector, producing the viral particles, and then transducing the T cells with the virus.
If you're starting from scratch, designing and cloning the CAR gene into a lentiviral vector could take several weeks to a few months. This includes time for designing the construct, creating and verifying the plasmid, and confirming its sequence.
Next, you would need to produce the lentiviral particles. This involves transfecting cells with the lentiviral vector plasmid and other necessary plasmids, harvesting the viral particles, and purifying and concentrating the virus. This part of the process typically takes a few days to a week.
Finally, you would use the virus to transduce T cells, expand the transduced T cells in culture, and prepare them for infusion into the patient. This part can take from 1 to 2 weeks.
Therefore, the overall process could take anywhere from several weeks to a few months. However, many steps in this process are often carried out in parallel, which can reduce the overall timeline"
Sign In
Follow the stocks
